All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1800+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Business Development

HBM Alpha Therapeutics licenses CRH antibody therapy to undisclosed partner for up to $395M, retaining Greater China rights
Antibody, congenital adrenal hyperplasia - Read more

Zymeworks notches $14M clinical milestone payment from GSK 
Bispecific antibody, antibody-drug conjugate, cancer, inflammatory, autoimmune, milestone payment - Read more

PRESENTED BY TLDR BIOTECH
What would you do with nearly 6,000 meticulously tagged biotech & pharma data points?

Over the past year, TLDR Biotech has been collecting and categorizing industry news across approvals, clinical trials, fundraises, partnerships, M&A, politics & policy, and much much more.

Each data point is tagged by drug modality, disease indication, tech area, and even more specific categories. For example:

🔍 Need to track all small molecule fundraises across oncology?

📈 Want a curated list of recent cell therapy clinical trials updates (both the successes and failures)?

💡 Looking for trends in Alzheimer's and Parkinson's disease partnerships?

We’re leveraging this resource to build tailored reports and curated insights for select clients—and we’re opening up limited access to interested parties.

If you’re interested, send us an email [email protected] with the subject line “6K BIOTECH DATA” and we’ll chat further.*

*If you’ve received this newsletter as an email, just hit reply!

⬇️ More Good News ⬇️

THE GOOD
Clinical Trials

AstraZeneca touts positive Ph3 data for camizestrant (estrogen receptor degrader) in certain forms of breast cancer
Small molecule, breast cancer - Read more

Madrigal Pharmaceuticals' Rezdiffra (targeting THR-β) shows significant liver stiffness reduction in compensated MASH cirrhosis patients in Ph3 MAESTRO-NAFLD-1 trial
Small molecule, metabolic dysfunction associated steatohepatitis (MASH), cirrhosis - Read more

Alligator Bioscience's mitazalimab (CD40 agonist) delivers “encouraging” survival data in Ph2 trial for metastatic pancreatic cancer, outperforming standard chemotherapy
Monoclonal antibody, pancreatic cancer - Read more

THE GOOD
Earnings & Finances

LEO Pharma reports double-digit sales growth, improved EBITDA, and successful launch of Anzupgo for chronic hand eczema in 2024
Small molecule, chronic hand eczema, topical - Read more

THE GOOD
Fundraises

Eikon Therapeutics $350.7M Series D, advancing biotechnology that combines engineering with molecular biology for drug discovery
Small molecule, melanoma, lung cancer - Read more

Enveda $20M Series C extension from Sanofi, AI platform focused on drug discovery by assessing molecules produced by living organisms
Drug discovery, AI - Read more

Ignota Labs $6.9M Seed, using AI platform to revive failed drug candidates with safety issues
Drug development, asset salvaging, AI - Read more

4Tissue raises €1.5M ($1.6M USD), developing bioresorbable hydrogel technology for tissue reconstruction
Regenerative medicine, hydrogel, drug delivery, tissue regeneration - Read more

NanoPhoria Bioscience €17.5M ($18.8M) EIC award, advancing heart failure product through first-in-human studies
Peptide, heart failure, drug delivery - Read more

THE GOOD
Investments

Eli Lilly commits a whopping $27B to build four new US production facilities
Site expansion, new site, domestic manufacturing - Read more

THE GOOD
IPOs

Alopexx plans $11M IPO to fund trials of infectious disease drugs, including a former Sanofi antibody
Vaccine, monoclonal antibody, antimicrobial resistance, infectious disease - Read more

Kestra Medical plans $154M IPO for wearable defibrillator, targeting expansion after serving 17,000 patients since 2022
Medical device, heart attack, defibrillator - Read more

THE GOOD
Lawsuits

Court orders CVS Health to provide documents for FTC's investigation into potentially anticompetitive practices of its PBM CVS Caremark
Pharmacy, pharmacy benefit manager - Read more [Paywall]

THE GOOD
Mergers & Acquisition

Quest Diagnostics acquiring Fresenius Medical Care's kidney dialysis testing portfolio
Medical device, hemodialysis, diagnostics - Read more

THE GOOD
Partnerships

Rakovina Therapeutics, Variational AI strengthen partnership for AI-driven cancer therapy development
Small molecule, cancer, AI, drug development - Read more

THE GOOD
Strategic Plans

ORIC Pharmaceuticals plans registrational trials for ORIC-944 (PRC2’s EED subunit inhibitor) in mCRPC and ORIC-114 (targeting EGFR, HER2) in NSCLC, extending cash runway into 2027
Small molecule, lung cancer, prostate cancer - Read more

Jazz Pharmaceuticals plans to diversify through strategic acquisitions in neuroscience, oncology, and rare diseases
M&A strategy - Read more

PRESENTED BY YOU?
Get the attention of 1800+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Business Development

Idorsia's global rights sale of hypertension drug Tryvio falls through, intensifying company's urgent need for funding
Small molecule, hypertension - Read more

THE BAD
Clinical Trial

BerGenBio scraps bemcentinib (targeting STK11) for non-small-cell lung cancer after poor Ph2a results, no exploring dreaded “strategic alternatives”
Small molecule, lung cancer - Read more

THE BAD
Earnings & Finances

Ginkgo Bioworks stock drops 13% as CEO cites uncertainty in government funding for 2025 revenue forecast
Biosecurity, cell engineering - Read more [Paywall]

THE BAD
Partnerships

Idorsia, Viatris restructure development cost agreement for selatogrel (targeting P2Y12 receptor) and cenerimod (S1P 1 receptor modulator), reducing Idorsia's contribution to $100M
Small molecule, heart attack, systemic lupus erythematosus, drug development - Read more

THE BAD
Politics & Policy

Merck & Co. expects Keytruda to face IRA price reductions in 2028, preceding its patent expiration and thus reducing US sales
Monoclonal antibody, cancer, Inflation Reduction Act - Read more

Medicare spending on diabetes drugs, especially GLP-1s like Ozempic, increased five-fold to $35.8 billion from 2019-2023
GLP-1, obesity, Medicare - Read more

House budget with major Medicaid cuts narrowly passes 217-215 despite healthcare industry opposition.
Medicaid - Read more

THE UGLY
Public Health

FDA cancels March advisory meeting on fall flu vaccine composition, disrupting six-month production cycle
Vaccine, flu, vaccine hesitancy - Read more

Child dies in Texas measles outbreak, first US measles death since 2015
Measles, Infectious disease, vaccine hesitancy - Read more [Paywall]

THE UGLY
Warning Letters, Form 483

FDA issues six-observation Form 483 to Piramal Pharma's Maharashtra plant for quality control and equipment issues
Manufacturing, quality concerns - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here